Zebrafish help us understand retinal diseases

Article

Biologists at the Florida State University, USA, have discovered a gene mutation in Zebrafish that determines if the cells develop as rods or as cones.

Biologists at the Florida State University, USA, have discovered a gene mutation in Zebrafish that determines if the cells develop as rods or as cones.

The landmark study, published in the Proceedings of the National Academy of Sciences, could shed new light on the molecular mechanisms underlying retinal development and, consequently provide new information on inherited retinal diseases in humans. Zebrafish eyes were used in the study as they have a mosaic of light-sensitive cells whose structure and functions are nearly identical to those of humans.

The allele, whose function was previously unknown, has been named "LOR," short for "lots-of-rods" because the mutation results in too many rods and fewer ultraviolet cones than in the normal eye.

"What is striking in this case," remarked lead author Karen Alvarez-Delfin, "is that the photoreceptor cell changes we observed in the retinas of zebrafish are opposite to the changes identified in Enhanced S-cone syndrome (ESCS), an inherited human retinal dystrophy in which the rods express genes usually only found in cones, eventually leading to blindness."

Furthermore, it was observed that while alterations in photoreceptor development in the human and mouse eyes lead to retinal degeneration, they did not in Zebrafish. Further studies hope to determine these differences in outcomes between mammals and fish, and why the human mutation leads to degenerative disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.